- Home
- XERS vs RGR Comparison
XERS vs RGR Comparison
Compare XERS & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- RGR
- Stock Information
- Founded
- XERS 2005
- RGR 1949
- Country
- XERS United States
- RGR United States
- Employees
- XERS N/A
- RGR N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- RGR Ordnance And Accessories
- Sector
- XERS Health Care
- RGR Industrials
- Exchange
- XERS Nasdaq
- RGR Nasdaq
- Market Cap
- XERS 628.7M
- RGR 615.7M
- IPO Year
- XERS 2018
- RGR N/A
- Fundamental
- Price
- XERS $5.07
- RGR $35.49
- Analyst Decision
- XERS Strong Buy
- RGR
- Analyst Count
- XERS 6
- RGR 0
- Target Price
- XERS $6.25
- RGR N/A
- AVG Volume (30 Days)
- XERS 2.2M
- RGR 212.0K
- Earning Date
- XERS 05-08-2025
- RGR 04-30-2025
- Dividend Yield
- XERS N/A
- RGR 1.99%
- EPS Growth
- XERS N/A
- RGR N/A
- EPS
- XERS N/A
- RGR 1.83
- Revenue
- XERS $222,551,000.00
- RGR $534,561,000.00
- Revenue This Year
- XERS $33.96
- RGR N/A
- Revenue Next Year
- XERS $19.87
- RGR $1.89
- P/E Ratio
- XERS N/A
- RGR $19.77
- Revenue Growth
- XERS 29.88
- RGR 0.65
- 52 Week Low
- XERS $1.96
- RGR $32.74
- 52 Week High
- XERS $6.07
- RGR $46.40
- Technical
- Relative Strength Index (RSI)
- XERS 54.35
- RGR 44.14
- Support Level
- XERS $4.71
- RGR $35.35
- Resistance Level
- XERS $5.09
- RGR $36.23
- Average True Range (ATR)
- XERS 0.22
- RGR 0.59
- MACD
- XERS -0.00
- RGR 0.07
- Stochastic Oscillator
- XERS 58.93
- RGR 20.38
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
About RGR Sturm Ruger & Company Inc.
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.